Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).

Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H

The Journal of clinical endocrinology and metabolism1 Feb 1993Cited by 93 (Europe PMC)

PMID7679397DOI10.1210/jcem.76.2.7679397PepBankPUB-07679397

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In elderly men with benign prostatic hyperplasia, Decapeptyl significantly reduced serum testosterone in all patients.
In plain wordsIn elderly men with prostate enlargement, Decapeptyl reduced testosterone in all patients.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum testosterone
Study
n = 17
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Our results showed that decapeptyl treatment caused a significant decrease in serum testosterone concentrations in all patients and resulted in a significant decrease in individual vertebral BMD in 10 of 17 patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939701
02HumanNon-randomized trialSafety outcome
In elderly men with benign prostatic hyperplasia, vertebral bone density significantly decreased in 10 of 17 patients during Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, bone density decreased in 10 of 17 patients during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseVertebral bone mineral density
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Patients with significant vertebral BMD decrease
10 patients
Decapeptyl-treated men (of 17)
Source sentences
Summary
Our results showed that decapeptyl treatment caused a significant decrease in serum testosterone concentrations in all patients and resulted in a significant decrease in individual vertebral BMD in 10 of 17 patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939702
03HumanNon-randomized trialSafety outcome
In elderly men with benign prostatic hyperplasia, bone density significantly decreased in 5 patients after 6 months of Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, bone density decreased in 5 patients after 6 months of Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone density at six months
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with significant BMD decrease
5 patients
after 6 months of Decapeptyl
Source sentences
Summary
A significant decrease in BMD was observed in 5 patients after 6 months of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939703
04HumanNon-randomized trialSafety outcome
In elderly men with benign prostatic hyperplasia, another 5 patients showed reduced bone density only after 12 months of Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, another 5 patients showed bone loss only after 12 months of Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseDelayed bone density decrease
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Patients with decreased BMD
5 patients
only after 12 months of Decapeptyl
Source sentences
Summary
Another 5 patients showed a decreased BMD only after 12 months.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939704
05HumanNon-randomized trialSafety outcome
In elderly men with benign prostatic hyperplasia, serum osteocalcin increased after Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, serum osteocalcin increased during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSerum osteocalcin
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6-12 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of osteocalcin, phosphorus, and alkaline phosphatase activity increased after 6-12 months of treatment with decapeptyl.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939705
06HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, serum phosphorus increased after Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, serum phosphorus increased during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSerum phosphorus
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6-12 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of osteocalcin, phosphorus, and alkaline phosphatase activity increased after 6-12 months of treatment with decapeptyl.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939706
07HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, alkaline phosphatase activity increased after Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, alkaline phosphatase activity increased during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAlkaline phosphatase activity
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6-12 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of osteocalcin, phosphorus, and alkaline phosphatase activity increased after 6-12 months of treatment with decapeptyl.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939707
08HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, serum calcium remained unchanged during Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, serum calcium remained unchanged during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSerum calcium
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Serum calcium, vitamin D metabolites, and PTH concentrations remained unchanged during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939708
09HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, vitamin D metabolites remained unchanged during Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, vitamin D metabolites remained unchanged during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeVitamin D metabolites
Study
n = 17
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Serum calcium, vitamin D metabolites, and PTH concentrations remained unchanged during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939709
10HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, PTH remained unchanged during Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, parathyroid hormone remained unchanged during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePTH
Study
n = 17
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Serum calcium, vitamin D metabolites, and PTH concentrations remained unchanged during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939710
11HumanNon-randomized trialOther
In elderly men with benign prostatic hyperplasia, urinary calcium excretion increased nonsignificantly after six months of Decapeptyl treatment.
In plain wordsIn elderly men with prostate enlargement, urinary calcium excretion did not change significantly after six months of Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeUrinary calcium excretion
Study
n = 17
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Urinary calcium excretion was slightly, but not significantly, increased after 6 months of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study we examined bone mineral density (BMD) and parameters of mineral metabolism in elderly men with benign prostatic hyperplasia before and during a hypoandrogenic state induced by the long-acting GnRH agonist D-Trp6-LHRH (decapeptyl).
Report a problemFND-0767939711

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.